May 12 (Reuters) – Danish drugmaker H Lundbeck raised its 2026 sales and earnings growth forecasts on Tuesday, helped by stronger U.S. demand for migraine treatment Vyepti and delayed generic competition for schizophrenia drug Abilify Maintena outside the U.S.
The company’s shares rose 4.2% after the announcement.
• Lundbeck now expects full-year revenue growth of 7% to 9% at constant exchange rates, up from 5% to 8%, and adjusted EBITDA growth of 8% to 14%, up from 4% to 12%.
• First-quarter revenue rose 21% at constant exchange rates to 7.13 billion crowns, though underlying growth was 13% after stripping out a planned one-off inventory build linked to its new partner-market model.
• Lundbeck’s first-quarter EBITDA came at 2.63 billion crowns, a rise of 26% from the previous year.
• “Across our pipeline, assets are advancing well, strengthening our long-term growth potential,” CEO Charl van Zyl said in an earnings report.
($1 = 6.3606 Danish crowns)
(Reporting by Jesus Calero and Vera Dvorakova in Gdansk; Editing by Sahal Muhammed)
